Asterias Biotherapeutics Inc (AST) Short Interest Down 2.6% in December

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) saw a large drop in short interest in the month of December. As of December 29th, there was short interest totalling 2,603,929 shares, a drop of 2.6% from the December 15th total of 2,672,506 shares. Based on an average trading volume of 143,188 shares, the short-interest ratio is currently 18.2 days. Approximately 8.2% of the shares of the stock are sold short.

Asterias Biotherapeutics (NYSEAMERICAN AST) opened at $2.45 on Friday. Asterias Biotherapeutics has a 12-month low of $1.95 and a 12-month high of $5.00. The stock has a market capitalization of $132.67, a P/E ratio of -3.77 and a beta of 1.30.

Several brokerages recently issued reports on AST. HC Wainwright set a $11.00 price objective on Asterias Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, January 8th. Zacks Investment Research downgraded Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $8.94.

TRADEMARK VIOLATION NOTICE: “Asterias Biotherapeutics Inc (AST) Short Interest Down 2.6% in December” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.themarketsdaily.com/2018/01/14/asterias-biotherapeutics-inc-ast-short-interest-down-2-6-in-december.html.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply